Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 68071-3150

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 68071-3150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3150 3

This is a medicine labeled as Cyclobenzaprine HCI 10mg. It comes in a bottle of 30 tablets. Each tablet is round and yellow with "283" marked on one side and "Lot: 000000" on the other side. The medication is a muscle relaxant, and it is only to be used with a doctor's prescription. The label warns to keep the bottle out of the reach of children and to store it at a temperature of 68-77°F. The label also encourages patients to seek medical advice if they experience side effects and provides them with the contact number of the FDA.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

This is a chart showing the percentages of possible side effects experienced with the use of Cyclobenzaprine HCI Tablets at different dosages, as well as a placebo. The listed side effects are drowsiness, dry mouth, fatigue, and headache.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

This is a summary of the clinical studies and surveillance program conducted with Cyclobenzaprine HCl tablets of 10 mg. The studies found that 39% of patients experienced drowsiness, 2% reported dry mouth, and 1% experienced dizziness. The surveillance program revealed a 16% incidence of drowsiness, 7% of dry mouth, and 3% of dizziness.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.